therapies

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

October 15, 2025 17:15 ET  | Source: Annovis Bio Inc. MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio,…

12 hours ago

Apollomics, Inc. Company Operational Continuity Update

October 13, 2025 21:22 ET  | Source: Apollomics Inc. FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc.…

2 days ago

Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes,…

3 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025 16:01 ET  | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics,…

2 weeks ago

LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly

NORWALK, Conn., Sept. 23, 2025 /PRNewswire/ -- Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio,…

3 weeks ago

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

September 12, 2025 07:00 ET  | Source: Cullinan Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics,…

1 month ago

KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025

RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) led Saudi healthcare…

1 month ago

Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced…

1 month ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…

2 months ago

Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment

Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for…

2 months ago